RIG-I-Like Receptor Signaling Pathway: A Complete Guide

The RIG-I-like receptor (RLR) signaling pathway is one of the most critical arms of innate antiviral immunity, providing cytosolic surveillance for viral RNA and mounting a rapid type I interferon response within hours of infection. RIG-I, MDA5, and LGP2 — the three members of the RLR family — act as molecular sentinels that distinguish viral nucleic acids from host RNA, making them essential components of pattern recognition in the cytoplasm. Beyond classical antiviral defense, dysregulation of the RLR pathway underpins autoimmune diseases, drives cancer immunosurveillance, and is actively exploited as a therapeutic target.

The RLR Family: RIG-I, MDA5, and LGP2

Three proteins constitute the RLR family, all encoded in the human genome and sharing a conserved DExD/H-box RNA helicase core domain and a C-terminal domain (CTD) responsible for RNA ligand binding. Despite this shared architecture, the three receptors differ markedly in their ligand preferences, domain organization, and signaling outputs.

RIG-I (DDX58; retinoic acid-inducible gene I) is the prototypical RLR. Its N-terminus carries two tandem caspase activation and recruitment domains (CARD1 and CARD2) that mediate downstream signaling; its CTD preferentially binds short double-stranded RNA (dsRNA) carrying a 5'-triphosphate group (5'ppp-RNA, typically <300 nt). This signature is a hallmark of RNA produced by negative-sense RNA viruses such as influenza A, Sendai virus (SeV), and vesicular stomatitis virus (VSV). RIG-I was first identified as an antiviral sensor by Yoneyama et al. in 2004 (Yoneyama et al., Nat Immunol 2004).

MDA5 (IFIH1; melanoma differentiation-associated protein 5) shares the helicase core and CARDs with RIG-I but recognizes long dsRNA (>1 kb) produced by positive-sense RNA viruses including picornaviruses (such as encephalomyocarditis virus, EMCV) and enteroviruses. The distinct ligand specificities of RIG-I and MDA5 were established by Kato and colleagues (Kato et al., Nature 2006). Importantly, gain-of-function variants in IFIH1 are associated with type 1 diabetes risk in humans — NOD mice with MDA5 knockout show significantly reduced insulitis — and with Aicardi-Goutières syndrome, underscoring MDA5's role beyond viral sensing.

LGP2 (DHX58; laboratory of genetics and physiology 2) lacks CARD domains entirely and therefore cannot directly activate MAVS-dependent signaling. Instead, LGP2 acts as a regulatory factor: it functions as a co-activator for MDA5-mediated signaling while exerting inhibitory effects on RIG-I at high dsRNA concentrations. This context-dependent regulatory role positions LGP2 as a fine-tuner of RLR output rather than a primary initiator.

RIG-I Activation and the MAVS Signaling Cascade

In the resting state, RIG-I is held in an autoinhibited conformation in which the CTD folds back onto the CARD2 domain, masking it from interaction with downstream partners. Viral infection releases this autoinhibition through a precisely ordered series of molecular events:

1. Ligand recognition: Short 5'ppp-dsRNA (produced during viral replication) engages the RIG-I CTD, inducing a conformational change that exposes the tandem CARDs.
2. K63-linked polyubiquitination: The E3 ubiquitin ligase TRIM25 catalyzes K63-linked polyubiquitin chains on Lys172 of the CARD2 domain. K63-linkage is a signaling modification — in contrast to K48-linked ubiquitination, which marks proteins for proteasomal degradation. This step is required for full RIG-I activation (Gack et al., Nature 2007).
3. CARD-CARD interaction with MAVS: The ubiquitinated CARD2 domain of RIG-I engages the single CARD domain of MAVS (Mitochondrial Antiviral-Signaling protein; also known as IPS-1/VISA/Cardif). MAVS was identified simultaneously by four groups in 2005 (Seth et al., Cell 2005).
4. MAVS prion-like oligomerization: CARD-CARD engagement triggers MAVS to adopt a self-propagating, prion-like functional amyloid filament structure on the outer mitochondrial membrane (OMM). MAVS also signals from peroxisomes and mitochondria-associated ER membranes (MAMs). The structural basis of MAVS oligomerization was resolved by Liu et al. (Liu et al., Science 2012).
5. TBK1/IKKε activation: MAVS filaments recruit TRAF3 and scaffold proteins (TANK, NAP1, SINTBAD), activating the kinase TBK1 and its homolog IKKε.
6. IRF3/IRF7 phosphorylation and nuclear translocation: TBK1 phosphorylates IRF3 at Ser396 (pSer396-IRF3), inducing homodimerization and nuclear translocation, where IRF3 binds the IFN-β promoter and drives IFN-β and IFN-α gene transcription.
7. NF-κB activation: In parallel, MAVS recruits TRAF2/TRAF5/TRAF6, activating IKKα/IKKβ to phosphorylate IκB and liberate NF-κB, driving transcription of pro-inflammatory cytokines including TNF-α, IL-6, and IL-12.

The canonical signaling cascade can be summarized as:

Viral Evasion of the RIG-I Pathway

Viruses that replicate in the cytoplasm face constant detection by RLRs and have evolved multiple strategies to subvert the pathway. Understanding these evasion mechanisms is essential for antiviral drug discovery and for interpreting in vitro experiments where viral countermeasures may attenuate RLR reporter readouts.

(a) 5'ppp masking and RNA capping. Many viruses cap their RNA to mimic host mRNA structure, preventing RIG-I recognition. Influenza virus NS1 protein additionally suppresses TRIM25-mediated ubiquitination of RIG-I CARD2, blocking activation at an early step.

(b) MAVS cleavage. Hepatitis C virus NS3/4A protease cleaves MAVS from the outer mitochondrial membrane at Cys508, physically severing the signaling scaffold. This single proteolytic event ablates both IRF3 and NF-κB branches of RLR signaling and is a major contributor to HCV's chronicity.

(c) Deubiquitination of signaling intermediates. SARS-CoV-2 papain-like protease (PLpro) functions as a deubiquitinase that removes K63-linked ubiquitin chains from STING and TRIM25, dampening both cGAS-STING and RLR-MAVS arms of innate immunity. This dual-pathway suppression is thought to contribute to the immunopathology of severe COVID-19 (Shin et al., Nature 2020; Freitas et al. 2020).

(d) IRF3 sequestration. Several herpesviruses encode proteins that bind and retain IRF3 in the cytoplasm, preventing nuclear translocation and IFN-β transcription.

RIG-I in Disease: Beyond Antiviral Defense

The RLR pathway has roles well beyond acute viral infection, and misregulated RLR signaling is increasingly recognized as a driver of chronic inflammatory and neoplastic disease.

Autoimmunity. Gain-of-function mutations in MDA5 (IFIH1) and RIG-I lead to constitutive type I IFN production without overt viral infection. IFIH1 variants are robustly associated with Aicardi-Goutières syndrome (AGS) and with systemic lupus erythematosus. In the context of type 1 diabetes, MDA5 may recognize endogenous dsRNA or enteroviral RNA in pancreatic beta cells: IFIH1 knockout in NOD mice reduces insulitis and delays diabetes onset, and human genome-wide association studies link IFIH1 polymorphisms to T1D risk (Funabiki et al., Cell 2014). The type I IFN signature detectable by IFN-β ELISA is now used as a biomarker to stratify patients with suspected interferonopathies.

Cancer immunosurveillance and immunotherapy. RIG-I is downregulated in several cancer types, including colorectal and melanoma, consistent with its role as a tumor suppressor. Conversely, pharmacological activation of RIG-I by synthetic 5'ppp-RNA or specific RIG-I agonists triggers cancer cell-intrinsic apoptosis in combination with type I IFN release, producing immunogenic cell death (ICD) that can prime adaptive antitumor immunity. RIG-I agonists are in early-phase clinical investigation as cancer immunotherapy agents, both as monotherapies and in combination with immune checkpoint blockade.

Epigenetic regulation. A study by Zhou et al. showed that the lysine methyltransferase MLL5 suppresses RIG-I-mediated antiviral response by facilitating STUB1-mediated K48-ubiquitination and proteasomal degradation of RIG-I, linking chromatin-modifying machinery to innate immune tone (Zhou et al., Nat Commun 2018).

Research Tools for Studying the RIG-I Pathway

Studying RLR signaling requires reliable reagents for quantifying pathway outputs (type I interferons, IRF3 phosphorylation) and for detecting pathway components (RIG-I, MAVS, IRF3 protein levels). BioHippo stocks a curated panel of research-grade tools validated for these applications.

Type I Interferon ELISA Kits — IFN-β is the primary transcriptional output of IRF3 activation and the gold-standard readout of RLR pathway activity. Available for human and mouse:

• Human IFN-Beta ELISA Kit PicoKine® (SKU: EK2286) — sandwich ELISA, sensitivity <2 pg/mL, serum and cell supernatant validated
• Mouse IFN-Beta ELISA Kit PicoKine® (SKU: EK2285) — sensitivity <10 pg/mL, validated in mouse infection models

IRF3 ELISA Kits — for quantifying total IRF3 protein levels in cell lysates and tissue homogenates:

• Human IRF3 ELISA Kit (SKU: ELK2074) — 0.16–10 ng/mL detection range, cell lysate and tissue homogenate
• Mouse IRF3 ELISA Kit (SKU: ELK2854)

RIG-I / DDX58 Detection

• RIG-I Antibody / DDX58 (SKU: F46991) — rabbit polyclonal, human/mouse reactivity, WB and ELISA validated
• Human DDX58 (RIG-I) ELISA Kit (SKU: EH7874) — 0.156–10 ng/mL, serum/plasma/lysate

MAVS Protein and Antibody

• MAVS Antibody (SKU: F43253) — rabbit polyclonal, human reactivity, WB and ELISA
• Recombinant Human MAVS Protein (SKU: P1785) — His-tagged, E. coli expression, 50–1000 μg available

Browse the full ELISA kit collection and primary antibody catalog for additional innate immunity targets including STING, TBK1, and IFN-γ.

Frequently Asked Questions

What is the RIG-I signaling pathway?

The RIG-I signaling pathway (formally the RIG-I-like receptor or RLR pathway) is a cytosolic innate immune surveillance system that detects viral RNA inside infected cells and triggers the production of type I interferons (IFN-α/β) and pro-inflammatory cytokines. It consists of three RNA sensors (RIG-I, MDA5, LGP2), the adaptor protein MAVS on the outer mitochondrial membrane, and downstream kinases TBK1/IKKε that phosphorylate and activate transcription factors IRF3 and IRF7, driving IFN gene expression within hours of infection.

How does RIG-I detect viruses?

RIG-I detects viruses by recognizing short double-stranded RNA bearing a 5'-triphosphate group (5'ppp-dsRNA) — a molecular signature present on the genomes and replication intermediates of negative-sense RNA viruses (influenza, Sendai virus, VSV) but absent from mature host mRNA, which carries a 5' cap structure. In the resting state, RIG-I is autoinhibited by its C-terminal domain folding over the CARD domains. When 5'ppp-dsRNA binds the CTD, the CARD domains are exposed, K63-ubiquitinated by TRIM25, and then engage MAVS to initiate the antiviral signal cascade.

What is MAVS in innate immunity?

MAVS (Mitochondrial Antiviral-Signaling protein; also called IPS-1, VISA, or Cardif) is the central adaptor protein of the RLR pathway. It resides on the outer mitochondrial membrane (and also on peroxisomes and MAMs) and carries a single N-terminal CARD domain that interacts with the activated RIG-I or MDA5 CARD domains. Upon interaction, MAVS forms a self-propagating, prion-like amyloid filament that amplifies the signal and recruits TRAF proteins and TBK1 to drive IRF3 phosphorylation and IFN gene transcription. Disruption of MAVS (e.g., by HCV NS3/4A protease cleavage) completely abrogates RLR-dependent IFN production.

What is the difference between RIG-I and MDA5?

RIG-I and MDA5 are both cytosolic RNA sensors with tandem N-terminal CARD domains and a shared DExD/H-box helicase core, but they differ in their RNA ligand specificity and the viruses they detect. RIG-I preferentially recognizes short dsRNA (<300 nt) with a 5'-triphosphate — hallmarks of negative-sense RNA virus genomes and replication intermediates. MDA5 recognizes long dsRNA (>1 kb) characteristic of positive-sense RNA viruses such as picornaviruses and enteroviruses. Because of this, RIG-I and MDA5 provide complementary coverage of the viral RNA universe, and many viruses are sensed by only one of the two.

How do viruses evade RIG-I signaling?

Viruses have evolved several strategies to evade RIG-I signaling: (1) RNA capping or 5'ppp masking prevents RIG-I recognition of viral RNA; (2) influenza NS1 protein blocks TRIM25-mediated K63-ubiquitination of RIG-I CARD2; (3) hepatitis C NS3/4A protease cleaves MAVS from the outer mitochondrial membrane, severing the signaling scaffold; (4) SARS-CoV-2 PLpro deubiquitinase removes K63-ubiquitin chains from TRIM25 and STING, dampening both RLR and cGAS-STING innate immune arms; (5) several herpesviruses sequester IRF3 in the cytoplasm to prevent IFN-β transcription.

What is the difference between RIG-I and cGAS-STING?

RIG-I and cGAS-STING are two distinct cytosolic innate immune sensing pathways that detect different nucleic acid species. RIG-I (and the other RLRs) detect RNA — specifically viral dsRNA or 5'ppp-RNA — and signal through MAVS on the mitochondrial membrane. cGAS (cyclic GMP-AMP synthase) detects cytosolic double-stranded DNA (dsDNA), whether from viral genomes, mitochondrial DNA leakage, or micronuclei from chromosomal instability. cGAS produces the second messenger cGAMP, which activates STING (on the ER membrane), ultimately also driving TBK1-IRF3 phosphorylation and IFN-β production. Both pathways converge on TBK1/IRF3/IFN-β, but their sensors, ligands, and adaptors are distinct.

References

Yoneyama M et al. (2004). The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5:730–737. doi:10.1038/ni1087

Kato H et al. (2006). Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:101–105. doi:10.1038/nature04271

Seth RB et al. (2005). Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF3. Cell 122:669–682. doi:10.1016/j.cell.2005.08.014

Liu S et al. (2012). MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades. eLife. Also: Hou F et al. (2011). MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 146:448–461.

Gack MU et al. (2007). TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446:916–920. doi:10.1038/nature05730

Funabiki M et al. (2014). Autoimmune disorders associated with gain of function of the intracellular sensor MDA5. Immunity 40:199–212. doi:10.1016/j.immuni.2013.12.014

Zhou P et al. (2018). MLL5 suppresses antiviral innate immune response by facilitating STUB1-mediated RIG-I degradation. Nat Commun 9:1243. doi:10.1038/s41467-018-03563-8

Loo Y-M & Gale M (2011). Immune signaling by RIG-I-like receptors. Immunity 34:680–692. doi:10.1016/j.immuni.2011.05.003